Transdermal system for timolol

Claim 3

A method according to claim 1 which comprises delivering timolol to the dermal surface at a zero order rate of from about 7 to about 15 micrograms per square centimeter per hour.

Claim 4

A method according to claim 2 wherein the rate for delivering timolol to the dermal surface is about 12 micrograms per square centimeter per hour.

Claim 5

A method according to claim 1 wherein the timolol is delivered to the dermal surface through a microporous membrane.

Claim 6

A method according to claim 1 wherein timolol is delivered to the dermal surface through a diffusion rate controlling membrane.

Claim 7

A method according to claim 1 wherein timolol is delivered to the dermal surface through a rate controlling adhesive layer.

Claim 8

A method according to claim 1 wherein timolol is delivered to the dermal surface through a combination of a membrane and a rate controlling adhesive layer.

Claim 11

A transdermal delivery system suitable for administering timolol for an extended period with little or no irritation to the dermal surface which comprises: (a) a backing member, said backing member being substantially impermeable to the drug, (b) a drug reservoir member, contiguous to and substantially coextensive with one face of said backing member and consisting essentially of timolol dispersed in a semisolid carrier, and (c) a rate controlling member superposed on the drug reservoir member and substantially coextensive therewith, said member controlling the flow of timolol from the reservoir to the skin surface of a zero order rate of from about 7 to no greater than 20 micrograms per square centimeter per hour, wherein said delivery system is prepared by (i) selecting a drug reservoir composition and a specific polymeric membrane or combination of membrane and adhesive as the rate controlling member, (ii) measuring the rate of release J of a drug reservoir composition through the selected rate controlling member or members into an isotonic phosphate buffer and (iii) determining for the selected membrane or membrane and adhesive, optimal parameters to provided the desired flux J, where J is described by the equation ##EQU7## wherein E is membrane porosity if the rate controlling member in a microporous membrane or is unity if the rate controlling member is a diffusion rate controlling membrane, D is diffusion coefficient of drug through the reservoir or of reservoir carrier medium in the micropores of a porous membrane, or of drug through a diffusion rate controlling membrane, K p is partition coefficient of drug membrane and reservoir, or between medium in the micropores and reservoir, C s is drug concentration in the reservoir, h is membrane or rate controlling member thickness, and wherein the optimal parameters are calculated by varying the porosity E and/or the thickness h of said membrane or membrane and adhesive.

Claim 12

A transdermal delivery system suitable for administering timolol for an extended period with little or no irritation to the dermal surface which comprises: (a) a backing member, said backing member being substantially impermeable to the drug, (b) a drug reservoir member, contiguous to and substantially coextensive with one face of said backing member and consisting essentially of timolol dispersed in a semisolid carrier, and (c) a rate controlling member superposed on the drug reservoir member and substantially coextensive therewith, said member controlling the flow of timolol from the reservoir to the skin surface of a zero order rate of from about 7 to no greater than 20 micrograms per square centimeter per hour, wherein said delivery system is prepared by (i) selecting a drug reservoir composition and a specific polymeric membrane or combination of membrane and adhesive as the rate controlling member, (ii) measuring the rate of release J of a drug reservoir composition through the selected rate controlling member or members into an isotonic phosphate buffer and (iii) determining for the selected membrane or membrane and adhesive, optimal parameters to provided the desired flux J, where J is described by the equation ##EQU7## wherein E is membrane porosity if the rate controlling member in a microporous membrane or is unity if the rate controlling member is a diffusion rate controlling membrane, D is diffusion coefficient of drug through the reservoir or of reservoir carrier medium in the micropores of a porous membrane, or of drug through a diffusion rate controlling membrane, K p is partition coefficient of drug membrane and reservoir, or between medium in the micropores and reservoir, C s is drug concentration in the reservoir, h is membrane or rate controlling member thickness, and wherein the optimal parameters are calculated by varying the porosity E and/or the thickness h of said membrane or membrane and adhesive.

Claim 13

A delivery system according to claim 9 wherein the carrier for the drug is a gelled mineral oil.

Claim 14

A delivery system according to claim 9 wherein the rate controlling member is a membrane.

Claim 15

A delivery system according to claim 9 wherein the membrane is of laminated multilayers and wherein the overall rate J net is determined by the relationship ##EQU8##

Claim 16

A delivery system according to claim 11 wherein the membrane is of microporous polypropylene.

Claim 17

A delivery system according to claim 11 wherein the membrane is of ethylene vinyl acetate.

Claim 18

A delivery system according to claim 11 wherein the membrane is of silicone.

Claim 19

A delivery system according to claim 11 wherein the membrane is of polyurethane.

Claim 20

A transdermal patch suitable for administering timolol for an extended period which comprises (a) a backing member of a material substantially impermeable to timolol; (b) a drug reservoir member adjacent to and coextensive with one face of said backing member, said drug reservoir member consisting essentially of timolol and a semi-solid gelled mineral oil carrier therefor, (c) a rate controlling member superposed on the drug reservoir member, said rate controlling member comprising at least one layer of a microporous membrane; and (d) an adhesive layer for affixing to the skin of a patient, wherein said patch delivers timolol at a zero order rate of from 7 to no greater than 20 micrograms per square centimeter per hour.

Claim 21

A transdermal patch suitable for administering timolol for an extended period which comprises (a) a backing member of a material substantially impermeable to timolol; (b) a drug reservoir member adjacent to and coextensive with one face of said backing member, said drug reservoir member consisting essentially of timolol and a semi-solid gelled mineral oil carrier therefor, (c) a rate controlling member superposed on the drug reservoir member, said rate controlling member comprising at least one layer of a microporous membrane; and (d) an adhesive layer for affixing to the skin of a patient, wherein said patch delivers timolol at a zero order rate of from 7 to no greater than 20 micrograms per square centimeter per hour.

Claim 22

A patch according to claim 17 wherein the carrier in the drug reservoir is gelled mineral oil and the microporous membrane of the rate controlling member is microporous polypropylene.

Claim 23

A patch according to claim 17 wherein the carrier in the drug reservoir member is gelled mineral oil and the rate controlling member is a film of polyisobutylene and mineral oil.

Claim 24

A patch according to claim 17 wherein the carrier in the drug reservoir member is gelled mineral oil and the rate controlling member is a combination of (a) a film of polyisobutylene and mineral oil and (b) microporous polypropylene membrane.